Merck & Co., Inc. manufactures Steglatro [1].
What is Steglatro used for?
Steglatro, also known by its generic name ertugliflozin, is a medication prescribed to improve blood sugar control in adults with type 2 diabetes mellitus [1]. It works by helping the kidneys remove excess sugar from the blood.
What other drugs are available for type 2 diabetes?
Other medications for type 2 diabetes include metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and other SGLT2 inhibitors [2]. Steglatro belongs to the class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors [1].
How does Steglatro work?
Steglatro functions by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine [1]. This mechanism helps to lower blood glucose levels.
When does Steglatro's patent expire?
Information regarding the specific patent expiry dates for Steglatro is available through patent tracking services [3].
Are there any potential side effects of Steglatro?
Common side effects of Steglatro can include urinary tract infections and upper respiratory tract infections [1]. More serious risks may involve dehydration, kidney problems, and ketoacidosis [1]. Patients should discuss any concerns with their healthcare provider.